Corticosteroid therapy benefits septic mice with adrenal insufficiency but harms septic mice without adrenal insufficiency

Critical Care Medicine

Volumn 43, Issue 11, 2015, Pages e490-e498

  Ai, Junting ^a   Guo, Ling ^a   Zheng, Zhong ^a   Wang, Shu Xia X ^a   Huang, Bing ^a   Li, Xiang An ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Adrenal insufficiency; Cecal ligation and puncture; Corticosteroid therapy; Scarb1; scavenger receptor BI; Sepsis

Indexed keywords

CORTICOSTEROID; FLUDROCORTISONE ACETATE; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 6; METHYLPREDNISOLONE ACETATE; NITRIC OXIDE; SCAVENGER RECEPTOR BI; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL GLAND; ADRENAL INSUFFICIENCY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CECAL LIGATION AND PUNCTURE; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; LABORATORY; LIGATION; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PERIPHERAL LYMPHOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUNCTURE; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; WILD TYPE; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; KNOCKOUT MOUSE; MALE; MORTALITY; PATHOPHYSIOLOGY; RANDOMIZATION; RISK ASSESSMENT; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADRENAL INSUFFICIENCY; ANIMALS; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, KNOCKOUT; RANDOM ALLOCATION; RISK ASSESSMENT; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84944456025     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001264     Document Type: Article

References (50)

1. Prigent H, Maxime V, Annane D: Science review: Mechanisms of impaired adrenal function in sepsis and molecular actions of glucocorticoids. Crit Care 2004; 8:243-252
2. Busillo JM, Cidlowski JA: The fve Rs of glucocorticoid action during infammation: Ready, reinforce, repress, resolve, and restore. Trends Endocrinol Metab 2013; 24:109-119
3. Coutinho AE, Chapman KE: The anti-infammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011; 335:2-13
4. Vandevyver S, Dejager L, Tuckermann J, et al: New insights into the anti-infammatory mechanisms of glucocorticoids: An emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology 2013; 154:993-1007
5. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637
6. Annane D, Sébille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fudrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
7. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124
8. Annane D, Bellissant E, Bollaert PE, et al: Corticosteroids in the treatment of severe sepsis and septic shock in adults: A systematic review. JAMA 2009; 301:2362-2375
9. Minneci PC, Deans KJ, Eichacker PQ, et al: The effects of steroids during sepsis depend on dose and severity of illness: An updated meta-analysis. Clin Microbiol Infect 2009; 15:308-318
10. Sligl WI, Milner DA Jr, Sundar S, et al: Safety and effcacy of corticosteroids for the treatment of septic shock: A systematic review and meta-analysis. Clin Infect Dis 2009; 49:93-101
11. Casserly B, Gerlach H, Phillips GS, et al: Low-dose steroids in adult septic shock: Results of the Surviving Sepsis Campaign. Intensive Care Med 2012; 38:1946-1954
12. Katsenos CS, Antonopoulou AN, Apostolidou EN, et al; Hellenic Sepsis Study Group: Early administration of hydrocortisone replacement after the advent of septic shock: Impact on survival and immune response. Crit Care Med 2014; 42:1651-1657
13. Greenberg SB, Coursin DB: Timing of corticosteroids in refractory septic shock: A key or wishful thinking?. Crit Care Med 2014; 42:1733-1735
14. Funk D, Doucette S, Pisipati A, et al; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group: Low-dose corticosteroid treatment in septic shock: A propensity-matching study. Crit Care Med 2014; 42:2333-2341
15. Allen KS, Kinasewitz GT: The pendulum of corticosteroids in sepsis swings again? Crit Care Med 2014; 42:2442-2443
16. Dellinger RP, Levy MM, Carlet JM, et al; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
17. Contrael KM, Killian AJ, Gregg SR, et al: Prescribing patterns of hydrocortisone in septic shock: A single-center experience of how surviving sepsis guidelines are interpreted and translated into bedside practice. Crit Care Med 2013; 41:2310-2317
18. Annane D, Maxime V, Ibrahim F, et al: Diagnosis of adrenal insuffciency in severe sepsis and septic shock. Am J Respir Crit Care Med 2006; 174:1319-1326
19. Bornstein SR: Predisposing factors for adrenal insuffciency. N Engl J Med 2009; 360:2328-2339
20. Briegel J, Sprung CL, Annane D, et al; CORTICUS Study Group: Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock. Intensive Care Med 2009; 35:2151-2156
21. Peeters RP, Hagendorf A, Vanhorebeek I, et al: Tissue mRNA expression of the glucocorticoid receptor and its splice variants in fatal critical illness. Clin Endocrinol (Oxf) 2009; 71:145-153
22. Krieger M: Charting the fate of the "good cholesterol": Identifcation and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 1999; 68:523-558
23. Zheng Z, Ai J, Li XA: Scavenger receptor class B type I and immune dysfunctions. Curr Opin Endocrinol Diabetes Obes 2014; 21:121-128
24. Li XA, Guo L, Asmis R, et al: Scavenger receptor BI prevents nitric oxide-induced cytotoxicity and endotoxin-induced death. Circ Res 2006; 98:e60-e65
25. Guo L, Song Z, Li M, et al: Scavenger receptor BI protects against septic death through its role in modulating infammatory response. J Biol Chem 2009; 284:19826-19834
26. Guo L, Zheng Z, Ai J, et al: Scavenger receptor BI and high-density lipoprotein regulate thymocyte apoptosis in sepsis. Arterioscler Thromb Vasc Biol 2014; 34:966-975
27. Guo L, Zheng Z, Ai J, et al: Comment on "Class B scavenger receptor types I and II and CD36 targeting improves sepsis survival and acute outcomes in mice". J Immunol 2012; 189:501; author reply 502
28. Guo L, Zheng Z, Ai J, et al: Hepatic scavenger receptor BI protects against polymicrobial-induced sepsis through promoting LPS clearance in mice. J Biol Chem 2014; 289:14666-14673
29. Cai L, Ji A, de Beer FC, et al: SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest 2008; 118:364-375
30. Cai L, Wang Z, Meyer JM, et al: Macrophage SR-BI regulates LPS-induced pro-infammatory signaling in mice and isolated macrophages. J Lipid Res 2012; 53:1472-1481
31. Gilibert S, Galle-Treger L, Moreau M, et al: Adrenocortical scavenger receptor class B type I defciency exacerbates endotoxic shock and precipitates sepsis-induced mortality in mice. J Immunol 2014; 193:817-826
32. Temel RE, Trigatti B, DeMattos RB, et al: Scavenger receptor class B, type I (SR-BI) is the major route for the delivery of high density lipoprotein cholesterol to the steroidogenic pathway in cultured mouse adrenocortical cells. Proc Natl Acad Sci USA 1997; 94:13600-13605
33. Hoekstra M, Meurs I, Koenders M, et al: Absence of HDL choles-teryl ester uptake in mice via SR-BI impairs an adequate adrenal glu-cocorticoid-mediated stress response to fasting. J Lipid Res 2008; 49:738-745
34. Hoekstra M, van der Sluis RJ, Van Eck M, et al: Adrenal-specifc scavenger receptor BI defciency induces glucocorticoid insuffciency and lowers plasma very-low-density and low-density lipoprotein levels in mice. Arterioscler Thromb Vasc Biol 2013; 33:e39-e46
35. Nemzek JA, Xiao HY, Minard AE, et al: Humane endpoints in shock research. Shock 2004; 21:17-25
36. Rhen T, Cidlowski JA: Antiinfammatory action of glucocorticoids-New mechanisms for old drugs. N Engl J Med 2005; 353:1711-1723
37. Smith LK, Cidlowski JA: Chapter 1-Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes. In: Progress in Brain Research. Luciano M (Ed). Oxford, Elsevier, 2010, pp 1-30
38. Ashwell JD, Lu FW, Vacchio MS: Glucocorticoids in T cell development and function. Annu Rev Immunol 2000; 18:309-345
39. Sainio EL, Lehtola T, Roininen P: Radioimmunoassay of total and free corticosterone in rat plasma: Measurement of the effect of different doses of corticosterone. Steroids 1988; 51:609-622
40. Uhl A, Czock D, Boehm BO, et al: Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. J Clin Pharm Ther 2002; 27:281-287
41. Hotchkiss RS, Tinsley KW, Swanson PE, et al: Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001; 166:6952-6963
42. Lim HY, Müller N, Herold MJ, et al: Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 2007; 122:47-53
43. Zhong HJ, Wang HY, Yang C, et al: Low concentrations of corticosterone exert stimulatory effects on macrophage function in a manner dependent on glucocorticoid receptors. Int J Endocrinol2013; 2013:405127
44. Ehrchen J, Steinmüller L, Barczyk K, et al: Glucocorticoids induce differentiation of a specifcally activated, anti-infammatory subtype of human monocytes. Blood 2007; 109:1265-1274
45. Webster JI, Sternberg EM: Role of the hypothalamic-pituitary-adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products. J Endocrinol 2004; 181:207-221
46. Leelahavanichkul A, Bocharov AV, Kurlander R, et al: Class B scavenger receptor types I and II and CD36 targeting improves sepsis survival and acute outcomes in mice. J Immunol 2012; 188:2749-2758
47. Rigotti A, Edelman ER, Seifert P, et al: Regulation by adrenocorticotropic hormone of the in vivo expression of scavenger receptor class B type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland. J Biol Chem 1996; 271:33545-33549
48. Huby T, Doucet C, Dachet C, et al: Knockdown expression and hepatic defciency reveal an atheroprotective role for SR-BI in liver and peripheral tissues. J Clin Invest 2006; 116:2767-2776
49. Kleiman A, Hübner S, Rodriguez Parkitna JM, et al: Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages. FASEB J 2012; 26:722-729
50. Rittirsch D, Flierl MA, Ward PA: Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8:776-787